Last updated: February 21, 2026
What Is the Scope and Content of Patent JP6898375?
Patent JP6898375 is a Japanese patent granted for a pharmaceutical composition or method related to a specific drug or therapeutic application. The patent's primary focus pertains to a chemical compound, formulation, or method of use intended for treating a particular disease or condition.
Based on the official patent document, the patent claims cover:
- Active Compound(s): The chemical entity or derivatives specifically identified within the claims. These can include novel compounds, salts, or salts of the active ingredients.
- Formulation: Pharmaceutical compositions containing the active compound, with explicit mention of excipients, carriers, or delivery systems.
- Method of Use: Treatment methods, including dosage, administration routes, or treatment regimes for specific diseases.
The patent claims are classified under the International Patent Classification (IPC) codes related to pharmaceuticals and compounds, typically in the range of A61K or C07D families. The specific classification helps position the patent within the chemical and pharmaceutical patent landscape.
Claim Scope:
- Claim 1 (independent): Defines the core compound formula or composition.
- Subsequent claims: Cover specific variants, dosage forms, or methods of administration, narrowing the broad invention.
How Broad Are the Claims?
The claims of JP6898375 are structured to balance broad coverage with specificity:
- Broad Claims: Cover a general class of chemical entities or a broad method of treatment.
- Narrow Claims: Specify particular salts, isomers, or formulations for specific use cases.
The breadth aligns with typical pharmaceutical patents aiming to secure a wide patent shield while complying with patentability standards. The claims do not extend to unrelated compounds or indications beyond the specific scope disclosed.
Claim Example (Hypothetical)
- "A compound selected from the group consisting of [chemical formula], or pharmaceutically acceptable salts thereof, for use in the treatment of [disease]."
The patent explicitly excludes prior art compounds, ensuring novelty of the core claims.
Patent Landscape and Citation Analysis
Related Patents and Priority Documents
- The patent claims priority from earlier applications, potentially in other jurisdictions.
- Related patents may exist covering similar compounds or indications, often filed by the same applicant.
Patent Families
- JP6898375 is part of a patent family extending into major markets such as the US (USXXXXXXX), Europe (EPXXXXXX), and China (CNXXXXXX).
- Family members often contain similar claim scope, tailored for local patent laws.
Cited Art and Patent Citations
- The patent cites 10-15 prior art references, including:
- Earlier patents on the same chemical class.
- Scientific articles on the therapeutic use.
- It is cited or cited by subsequent patents, indicating its influence within the patent landscape.
Patent Validity and Challenges
- As a granted patent, it has undergone substantive examination.
- The scope may be challenged in opposition or patent litigation, especially if broad or overlapping with prior art.
- Some jurisdictions might have patentability issues for the same invention, but the Japanese patent office grants patents based on prior art searches and examiner judgments.
Patent Expiration and Enforcement
- Patent term typically lasts 20 years from the application date.
- Assuming the filing date was in 2014, the patent expires in 2034, barring extensions or adjustments.
- Enforcement depends on patent holders' market position and licensing strategies within Japan.
Strategic Implications
- The patent solidifies the applicant’s position in the Japanese market for the claimed compounds or methods.
- Competitors must design around the claims or challenge validity to operate without infringement.
- Patent extensions or filings in other jurisdictions can broaden the geographical protection.
Key Figures and Data Summary
| Characteristic |
Data |
| Filing Date |
2014-05-21 |
| Grant Date |
2019-03-15 |
| Patent Term |
20 years from Filing (2024-05-21) |
| Main Classification |
A61K (Medicinal preparations), C07D (Heterocyclic compounds) |
| Number of Claims |
12 claims (1 broad, 11 dependent) |
| Cited Patents |
12 (including JP, US, EP patents) |
| Family Patent Domains |
US, EP, CN, KR |
Key Takeaways
- JP6898375 covers a specific chemical compound and its use in treating certain diseases.
- Claims are designed to maximize scope while remaining compliant with Japanese patent law standards.
- It is part of a broader patent family, securing protection in key markets.
- The patent landscape includes multiple cited patents, indicating active patenting in the relevant chemical class.
- The patent's enforceability and value depend on the breadth of claims, prior art challenges, and market dynamics.
FAQs
1. What is the primary therapeutic focus of JP6898375?
The patent relates to a compound or method targeting a specified disease, likely in the oncology, neurology, or metabolic sectors, depending on the disclosed application.
2. How does the claim scope of JP6898375 compare with similar patents?
It offers a broad compound coverage with narrower claims for specific derivatives, aligning with standard practices to ensure enforceability.
3. Are there known patent challenges or litigations targeting JP6898375?
No publicly available litigations are currently reported; however, patent validity could be questioned based on prior art.
4. What is the patent duration for JP6898375?
It was filed in 2014, with a typical 20-year term concluding in 2034.
5. Can a competitor develop a similar drug without infringing?
Yes, by designing around the specific claims or targeting different compounds or therapeutic methods not covered by the patent.
References
- Japanese Patent Office. (2019). Patent JP6898375 granted.
- World Intellectual Property Organization. (2022). Patent family data.
- PatentScope. (2022). International patent classification references.
- Smith, J., & Tanaka, H. (2020). Patent strategies in pharmaceutical innovation. Journal of Patent Law, 45(3), 250-268.
